Compare ARI & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | BHVN |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2009 | 2022 |
| Metric | ARI | BHVN |
|---|---|---|
| Price | $10.72 | $10.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $11.00 | ★ $27.69 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 05-14-2026 | 06-08-2026 |
| Dividend Yield | ★ 9.48% | N/A |
| EPS Growth | ★ 183.51 | 26.08 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $271,589,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.92 | N/A |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.70 | $7.48 |
| 52 Week High | $11.21 | $31.80 |
| Indicator | ARI | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 40.76 |
| Support Level | $9.57 | $8.40 |
| Resistance Level | $11.12 | $11.92 |
| Average True Range (ATR) | 0.21 | 0.64 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 69.66 | 23.95 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.